AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12206443
Drug: 9-month exercise
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-month exercise intervention (goal: at least 10 miles of weekly brisk walking or jogging)
Trial: 1657656
Drug: 10.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 g/day dietary fibre
Trial: 1657656
Drug: 21 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 g/day dietary fibre
Trial: 7117309
Drug: L-dopa and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa and/or physostigmine treatment
Trial: 30357263
Drug: DHA+AA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA+AA (200 mg DHA and 200 mg AA daily for 6 months)
Trial: 27693978
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture plus fluoxetine (n=22)
Trial: 27693978
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture plus fluoxetine (n=24)
Trial: 23949801
Drug: Low-glucose regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-glucose regimen (combination of dextrose-based solution, icodextrin and amino acids)
Trial: 23949801
Drug: Dextrose solutions
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose solutions only (control group)
Trial: 16142502
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or antiresorptive drugs (including hormone replacement therapy and alendronate)
Trial: 14727367
Drug: Oral antiphlogistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiphlogistic medicinal granules only (Group A)
Trial: 14727367
Drug: Oral antiphlogistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiphlogistic medicinal granules + retention enema (Group B)
Trial: 14727367
Drug: Oral antiphlogistic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiphlogistic medicinal granules + rectal (Group C)
Trial: 11527612
Drug: Eptifibatide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (two 180 microg/kg boluses 10 min apart and continuous infusion of 2 microg/kg per min)
Trial: 9547132
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg once a day, titrated to a maximum of 200 mg)
Trial: 9547132
Drug: Sertraline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (2 full years treatment)
Trial: 9547132
Drug: Sertraline (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (during double-blind phase)
Trial: 27194317
Drug: Nurse-led lymphoma
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led lymphoma survivorship clinic with three face-to-face appointments and tailored resources, survivorship care plan and treatment summary (SCP TS).
Trial: 27194317
Drug: Usual post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Usual post-treatment care.
Trial: 24139256
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine hydrochloride with 12.5 μg/mL epinephrine
Trial: 24139256
Drug: physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline solution
Trial: 12795037
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment for progressive MS
Trial: 1626732
Drug: Pentoxifylline, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline, oral administration at a dose of 1,200 mg daily during healing and 400 mg daily during ulcer-free intervals
Trial: 1626732
Drug: Deferoxamine, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine, intravenous dose of 20 mg/kg
Trial: 3890639
Drug: Atropine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.05 mg/kg)
Trial: 31780002
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology (15 min on each foot, total 30 min, twice a week for six weeks)
Trial: 27097163
Drug: Antimicrobial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial treatment for 8 weeks
Trial: 16860046
Drug: 4-day hormone-free
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-day hormone-free interval (HFI)
Trial: 16860046
Drug: 7-day hormone-free
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day hormone-free interval (HFI)
Trial: 12826045
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 as a 3-h infusion followed by carboplatin at AUC 6 every 3 weeks for three courses
Trial: 1321056
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (1.6 mg.day‐1 for 7 days)
Trial: 1321056
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg.day‐1 for 3 days)
Trial: 1321056
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral dexamethasone (8 mg.day‐1 for 2 days)
Trial: 6148382
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg LI 32-468
Trial: 6148382
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg LI 32-468
Trial: 6148382
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg LI 32-468
Trial: 31682194
Drug: Mentalization-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-Based Treatment in a day hospital setting (MBT-DH)
Trial: 31682194
Drug: Specialist Treatment
RxNorm normalized name: Centrum Specialist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist Treatment as Usual (S-TAU)
Trial: 30448598
Drug: Besifovir dipivoxil
RxNorm normalized name: Besifovir dipivoxil
DrugBank: Besifovir dipivoxil (DB05020)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifovir dipivoxil maleate (BSV) 150 mg
Trial: 23839751
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (20 g daily)
Trial: 29440154
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surgical treatment
Trial: 18645042
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment by functional bracing
Trial: 11194948
Drug: 3D-conformal-radiation therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D-conformal-radiation therapy (3D-CRT)
Trial: 11194948
Drug: 3D-conformal-radiation therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D-conformal-radiation therapy (3D-CRT) with escalated dose (+10 or 15%)
Trial: 8690970
Drug: THELEP‐recommended regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THELEP‐recommended regimen (600 mg rifampin, 600 mg clofazimine supervised on two consecutive days monthly, 225 mg diacetyl diaminodiphenylsulfone bimonthly, 100 mg dapsone daily unsupervised)
Trial: 8690970
Drug: Conventional MDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional MDT (600 mg rifampin, 300 mg clofazimine supervised once a month, 100 mg dapsone daily unsupervised, 50 mg clofazimine daily unsupervised)
Trial: 24380385
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction advice in the form of an Energy Prescription (EP)
Trial: 20666814
Drug: Interoperative irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interoperative irrigation with sterile saline solution
Trial: 18239197
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg trihexyphenidyl
Trial: 16603147
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Fe daily
Trial: 16603147
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Fe twice weekly
Trial: 12453547
Drug: Nebivolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (2.5 and 5 mg)
Trial: 7717236
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.6 mg/kg 20-30 min before cystourethrography
Trial: 2038109
Drug: ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg
Trial: 31945548
Drug: aPDT as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aPDT as an adjunct to ultrasonic scaling (US)
Trial: 31945548
Drug: PBM as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBM as an adjunct to ultrasonic scaling (US)
Trial: 23802640
Drug: Ascorbic acid,
RxNorm normalized name: ASCORBIC ACID, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascorbic acid, 500 mg every eight hours, administered three times per day for 48 hours prior to bleaching sessions.
Trial: 23802640
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered three times per day for 48 hours prior to bleaching sessions.
Trial: 21416238
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + subgingival minocycline administration
Trial: 19258143
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of 1% lidocaine
Trial: 17445928
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) - 50 Gy/25 fx/5 weeks followed by 12 Gy/2 fx of high-dose-rate intra-lumenal brachytherapy (initially), later modified to 66 Gy/33 fx/6.5 weeks.
Trial: 17445928
Drug: Cisplatin chemo-radiotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemo-radiotherapy (CRT) - identical radiotherapy with concurrent weekly cisplatin at 35 mg/m2 for 6-7 cycles.
Trial: 10440800
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A and B vaccine (two-dose schedule)
Trial: 10440800
Drug: Monovalent vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent vaccines (two-dose schedule)
Trial: 2117799
Drug: OKT3 as
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 as a prophylactic agent
Trial: 371743
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg i.m.)
Trial: 371743
Drug: Cefazolin (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1.1 g i.m.)
Trial: 30778649
Drug: Betrixaban (full-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betrixaban (full-dose stratum)
Trial: 30778649
Drug: Enoxaparin (full-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (full-dose stratum)
Trial: 17910330
Drug: Levocetirizine, 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine, 0.125 mg/kg, twice daily for 18 months
Trial: 8877910
Drug: 13C-urea breath
RxNorm normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 13C-urea breath test (13C-UBT) with 38 mg 13C-urea
Trial: 3741533
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (0.48 g of theophylline-ethylenediamine, TE)
Trial: 3741533
Drug: Retention enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retention enema (400 mg theophylline, 600 mg diprophylline, 600 mg proxyphylline, TDP)
Trial: 29239764
Drug: Dipeptidyl peptidase
RxNorm normalized name: Dipeptidyl peptidase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptidyl peptidase 4 inhibitors (DPP‐4i)
Trial: 1909748
Drug: Transdermal nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitrate therapy
Trial: 1909748
Drug: Oral nitrate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nitrate therapy
Trial: 6397454
Drug: Indomethacin together
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin together with low dose dopamine infusion
Trial: 24524214
Drug: 9-week online
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-week online insomnia treatment programme, Sleep Healthy Using The internet (SHUTi)
Trial: 20231896
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium stibogluconate (SSG) 20mg/kg/day for ten doses
Trial: 20231896
Drug: Localized ThermoMed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized ThermoMed (TM) device heat treatment (applied at 50 degrees C for 30 seconds) in one session
Trial: 17398320
Drug: 5 IU/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU/ml low-molecular-weight heparin (LMWH) and 200 mug/ml 5-Fluorouracil (5FU) added to the perioperative infusion fluid
Trial: 12188401
Drug: Simvastatin (Zocor),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (Zocor), dosage 10 mg
Trial: 12188401
Drug: Generic simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic simvastatin (Unison), dosage 10 mg
Trial: 8887188
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) therapy after GnRH-a administration
Trial: 8887188
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (GnRH-a plus OC 'addback') for six months
Trial: 30302335
Drug: Once daily,
RxNorm normalized name: Austedo XR Once Daily, 4 Week Titration Pack, 6 MG / 12 MG / 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Trial: 30302335
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily budesonide/formoterol (BUD/FOR) 400/12 μg
Trial: 21159473
Drug: Diphenhydramine 20
RxNorm normalized name: dextromethorphan/phenylephrine/acetaminophen/diphenhydramine 20 mg-10 mg-575 mg-37.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 20 mg
Trial: 20137360
Drug: Morphine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.15 mg/kg; maximum 20 mg)
Trial: 16512103
Drug: Yogurt containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt containing Bifidobacterium DN-173 010 (200 g once daily for 2 weeks)
Trial: 16512103
Drug: Control yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control yogurt without viable bacteria (200 g once daily for 2 weeks)
Trial: 9951429
Drug: R-568 (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-568 (calcium receptor agonist)
Trial: 9951429
Drug: R-568 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-568 (80 to 160 mg doses)
Trial: 7844610
Drug: Diethyldithiocarbamate (DDTC)
RxNorm normalized name: diethyldithiocarbamate
DrugBank: Ditiocarb (DB02520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethyldithiocarbamate (DDTC) 1.6 g/m2 over 4 hours, administered intravenously every 4 weeks for six cycles
Trial: 7844610
Drug: Placebo (PB),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PB), administered intravenously every 4 weeks for six cycles
Trial: 2189954
Drug: MVAC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVAC chemotherapy
Trial: 2189954
Drug: CISCA chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CISCA chemotherapy
Trial: 446321
Drug: Additional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment with piracetam (Normabrain, Nootrop, 9 g/d intravenously)
Trial: 26031193
Drug: 5-HTP (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HTP (100 mg orally)
Trial: 23609398
Drug: haloperidol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (2.5 mg) + midazolam (7.5 mg)
Trial: 23609398
Drug: haloperidol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (2.5 mg) + promethazine (25 mg)
Trial: 23609398
Drug: ziprasidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone (10 mg)
Trial: 21893650
Drug: Cycled therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycled therapy (tobramycin inhalation solution 300 mg twice a day for 28 days + oral ciprofloxacin 15-20 mg/kg twice a day for 14 days every quarter)
Trial: 21893650
Drug: Culture-based therapy
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture-based therapy (same treatments only during quarters with positive P aeruginosa cultures)
Trial: 21893650
Drug: Ciprofloxacin (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (15-20 mg/kg twice a day for 14 days every quarter)
Trial: 21893650
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo for 14 days every quarter)
Trial: 21893650
Drug: Cycled therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycled therapy
Trial: 21893650
Drug: Culture-based therapy
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture-based therapy
Trial: 15363569
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg clomipramine
Trial: 11731062
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTXA) injection
Trial: 9230003
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B lipid complex at 5 mg/kg total dose (1 mg/kg per day for 5 days)
Trial: 9230003
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B lipid complex at 10 mg/kg total dose (2 mg/kg per day for 5 days)
Trial: 9230003
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B lipid complex at 15 mg/kg total dose (3 mg/kg per day for 5 days)
Trial: 2902812
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg kg‐1 cimetidine (groups 3 and 5)
Trial: 2902812
Drug: 0.2‐0.3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2‐0.3 mg kg‐1 etomidate (groups 2 and 3)
Trial: 2902812
Drug: 2‐3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐3 mg kg‐1 thiopentone (groups 1, 4, 5 and 6)
Trial: 2902812
Drug: 0.08 mg
RxNorm normalized name: mestranol 0.08 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08 mg kg‐1 vecuronium
Trial: 2902812
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg kg‐1 ranitidine (group 6)
Trial: 2902812
Drug: 0.002 mg
RxNorm normalized name: niacin 0.002 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.002 mg kg‐1 fentanyl and 0.01 mg kg‐1 lormetazepam
Trial: 25315258
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice daily
Trial: 21884529
Drug: Azithromycin (AZM)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZM) 500 mg for 3 days during the first week, followed by 500 mg per week for the next 11 weeks
Trial: 17898353
Drug: Amisulpride (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (dopamine D(2)/D(3) antagonist)
Trial: 15485015
Drug: Cortivazol (Altim)
RxNorm normalized name: cortivazol
DrugBank: Cortivazol (DB13003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortivazol (Altim) 3.75 mg
Trial: 11152924
Drug: Vaginal preparation
RxNorm normalized name: Trichomonas vaginalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal preparation with povidone iodine
Trial: 11152924
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation (control)